Marrying immunotherapy with chemotherapy: why say IDO?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16166276.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Activation of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) in cancer cells facilitates immune escape. A recent study now shows how small-molecule inhibitors of IDO can be used to leverage the efficacy of traditional chemotherapeutic drugs that are used to treat cancer in the clinic. By promoting antitumor immune responses in combination with cytotoxic chemotherapy, IDO inhibitors may offer a drug-based strategy to more effectively attack systemic cancer.
Medical subject headings
- Antineoplastic Agents
- Enzyme Inhibitors
- Immunotherapy
- Indoleamine-Pyrrole 2,3,-Dioxygenase
- Neoplasms